2023 PDA Microbial Data Deviation Investigations Workshop

Washington, DC
Ask a Question
Program Highlights

Takeaways include:

  • Understanding how to search for root cause and resolving sterile product microbial mishaps
  • Getting insights and points to consider on conducting laboratory investigations
  • Hearing about the current FDA guidance on properly executing microbial data deviations
  • Learning how to de-risk microbial excursion potential based on smart facility and utility design, and what to do for legacy facility designs
  • Gaining tools for determining potential sources of contamination when assessing objectionable organisms found in non-sterile drug products

A key feature of this interactive workshop is that every plenary session will include a case study!

Microbiological data deviations result from microbial test results that fall outside the product specification or acceptance criterion established in a drug application, drug master file, official compendia, good manufacturing practice regulations, or internally by the manufacturer. The term "microbial data deviation" is preferred to "out-of-specification" or "out-of-limit result," as most microbiological tests, especially in a sterile product manufacturing facility, are in-process tests, not finished- product tests that must meet a regulatory-approved specification. This is an area of continued focus for regulatory authorities during inspections and document reviews. However, it is also an area of limited guidance from health authorities.

Attend the 2023 PDA Microbial Data Deviation Investigations Workshop to provide additional information following the 2022 MDDI Conference as well as get both a recap of the newly developed PDA Technical Report No. 88: Microbial Data Deviation Investigations in the Pharmaceutical Industry (TR88), as well as real world examples that can be used to develop and improve your current approaches and strategies to manage these events.

PROGRAM PLANNING COMMITTEE

  • Marc Glogovsky, ValSource, Inc. (Co-Chair)
  • Christopher Murdock, Bristol Myers Squibb (Co-Chair)
  • Elizabeth Brockson, Takeda
  • Vanessa Figueroa, Quality Executive Partners
  • Djamila Harouaka, U.S. FDA
  • Paula Peacos, ValSource, Inc.
  • James Polarine, STERIS Corporation
  • Kim Sobien, ValSource, Inc.

Standard Pricing

Standard Member Price

$2,095

GovernmentMember Only

$895

Health AuthorityMember Only

$895

Early Career ProfessionalMember Only

$1,395

StudentMember Only

$595

AcademicMember Only

$895

Non-Member

$2,495

See Qualifying Criteria for Member Types.

GROUP REGISTRATION DISCOUNT: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].

Day 1

WEDNESDAY, 04 OCTOBER

12:00 – 18:00 | Registration Open

13:30 – 15:15 | P1: Navigating Laboratory Investigations: Don't Get Lost in the Maze!
Moderator: Paula J. Peacos, MS,
Senior Consultant, ValSource, Inc.

This session will delve into the unique aspects of a typical microbiological laboratory investigation. The presenters will be drawing on their combined 100 years of industry experience to provide practical and fascinating insights into the twists and turns that arise in conducting what would be expected to be a straightforward laboratory investigation. Both new and experienced laboratory investigators will discover useful insights and points to consider when conducting their own laboratory investigations.

13:30 | Welcome Remarks from Workshop Co-Chairs
Marc Glogovsky, MS,
Business Unit Manager/Senior Consultant - Microbiology, ValSource, Inc.
Christopher A. Murdock, PhD, CQA, Senior Director, Global Quality Systems, Bristol Myers Squibb

13:45 | Assessing the Impact and Risks Associated with Recovered Microorganisms in Laboratory Investigations
Susan Daniel, MBA, MA,
Senior Manager of Cell and Gene Therapeutics, Johnson & Johnson

14:05 | Endotoxin Investigations: A Practical Approach for Laboratory Investigators
Owen Jamison,
Principal Biologist, Eli Lilly and Company

14:25 | Case Study: Seek and Ye Shall Find: Laboratory Investigations for Sterility Test Failures
Chris Knutsen, PhD,
Scientific Director, Bristol Myers Squibb

14:55 | Q&A

15:15 – 15:45 | Networking Break in the Exhibit Area

15:45 – 17:15 | P2: What to do Without a CFU?
Moderator: Marc Glogovsky, MS,
Business Unit Manager/Senior Consultant - Microbiology, ValSource, Inc.

With the recent “blessing” bestowed upon our industry from within the new EU/PICS Annex 1 guideline, there is a resurgence in the desire to select and implement a rapid microbiological method (RMM). The presentations and case studies in this session will guide the participants through different method utilizations as well as deciphering the data that may not conform to traditional methods (CFU). Attendees will have an opportunity to work through a laboratory-based investigation, while taking advantage of microbiological tools that provide contamination feedback in as little as a few hours.

15:45 | Modern Microbiological Methods and Associated Data Analysis
Frederic B. Ayers,
Senior Consultant, ValSource, Inc.

16:05 | A Modern and Holistic Approach in Pyrogen Testing
Christoph Hansy,
Associate Director/Global Sterility Assurance and Microbiology, Takeda

16:25 | Case Study on Rapid Recovery: How to Conduct Meaningful Root/Cause Analysis with Rapid Methods
Stacey N. Ramsey, MS, SM(NRCM),
Senior Manager, Celsis Applications, Charles River Laboratories
Anthony Grilli, CEO and Laboratory Director, Focus Laboratories

16:55 | Q&A

17:15 – 18:30 | Networking Reception in the Exhibit Area

Day 2

THURSDAY, 05 OCTOBER

07:00 – 16:00 | Registration Open

07:00 – 08:00 | Continental Breakfast

08:00 – 09:30 | P3: Facilities and Utilities: Smarter Design, Reduced Risk
Moderator: Elizabeth Brockson, MPH, VPH,
Aseptic Processing and Sterility Assurance Lead, Takeda

Has your facility ever suffered from unplanned down time? Do you really understand what goes on above the ceiling and behind the walls of your cleanrooms? Attendees of this session will learn how to de-risk microbial excursion potential based on smart facility and utility design, and what to do for legacy facility designs.

08:00 | Are There Holes in Your HEPA-Filter Integrity Testing?
Abby A. Roth, CMQ/OE,
Owner/Microbiologist, Pure Microbiology, LLC

08:20 | Leveraging Pre-Fabricated Solutions to Reduce Risk
Peter J. Makowenskyj, MEng,
Director of Design Consulting, G-CON Manufacturing, Inc.

08:40 | A New Angle? Or a Dead End? A Case Study on Purified Water System Excursions
Djamila Harouaka, PhD,
Senior Scientific Advisor, OQS, OPQ, CDER, U.S. FDA

09:10 | Q&A

09:30 – 10:00 | Networking Break in the Exhibit Area

10:00 – 11:30 | P4: Navigating the Realm of Non-Sterile Drug Product Investigations
Moderator: Vanessa Vasadi Figueroa, MA,
Executive Director, Microbiology, Quality Executive Partners, Inc.

Principles for investigating non-sterile drug products should generally follow the same rules as other types of microbial investigations, as the goal for finding the source of contamination remains the same. This segment will teach a variety of tools for determining the potential sources of contamination when assessing objectionable organisms found in non-sterile drug products, and for understanding the current FDA guidance on properly executing microbial data deviations. A case study will also provide background on a black mold isolated from an ISO 8 manufacturing area, and then guide attendees through an effective root cause analysis exercise for identifying its source.

10:00 | To Release or Not to Release? Assessment for Objectionable Organisms in Non-Sterile Products
Christine Sherman,
Global Sterility Assurance & Microbiology, Takeda

10:20 | Non-Sterile Drug Microbial Deviations: A CDER Microbiologist's Perspective
John W. Metcalfe, PhD,
Quality Assessment Lead, Division of Microbiology Assessment, OPQ, CDER, U.S. FDA

10:40 | Case Study: A Day in the Life of a Black Mold
James N. Polarine, Jr., MA,
Senior Technical Service Manager, STERIS Corporation

11:10 | Q&A

11:30 – 12:30 | Lunch

12:30 – 14:00 | P5: Most Probable at Best: Investigating Sterile Product Microbial Data Deviations
Moderator: Kim Sobien, MBA,
Senior Consultant - Microbiology, ValSource, Inc.

Investigating microbial data deviations for sterile products can be an arduous task that requires a trained eye and a deep curiosity for solving puzzles. Our presenters will take us through three adventures in aseptic manufacturing issues where knowledge and skill led to unraveling the mystery of microbial contamination. This session will help you learn how to search for root cause in all the right places and resolve sterile product microbial mishaps.

12:30 | Investigating the Inevitable: Going Back to Where it Starts
Irving Ford, MSc,
VP of Quality, Adaptimmune

12:50 | Investigating Environmental Monitoring Excursions from Classified Cleanrooms
Phil Duncanson, PhD,
Chief Microbiologist, AstraZeneca

13:10 | Case Study: 503B Sterility Investigations with Alternative Microbiological Methods
Amy L. Blubaugh,
Microbiology Manager, SCA Pharma

13:40 | Q&A

14:00 – 14:30 | Networking Break in the Exhibit Area

14:30 – 16:00 | P6: Panel Discussion and Wrap Up
Moderator: Christopher A. Murdock, PhD, CQA,
Senior Director, Global Quality Systems, Bristol Myers Squibb

We will wrap up our Workshop with a panel discussion, including one presenter from each of our plenaries. Attendees will have the opportunity to ask any remaining questions regarding the importance of performing thorough microbiological investigations. A thorough investigations offers us the opportunity to identify problems, the root cause and implement meaningful CAPA to mitigate potential repeat events, thus improving our processes and even more importantly ensuring timely supply of necessary medicines to our patients. We hope you can bring back what was learned throughout the Workshop and implement it with your organizations.

15:00 | Panel Discussion
Frederic B. Ayers, 
Senior Consultant, ValSource, Inc.
Irving Ford, MSc, VP of Quality, Adaptimmune
Djamila Harouaka, PhD, Senior Scientific Advisor, OPQ, CDER, U.S. FDA
Chris Knutsen, PhD, Scientific Director, Bristol Myers Squibb
John W. Metcalfe, PhD, Quality Assessment Lead, Division of Microbiology Assessment, OPQ, CDER, U.S. FDA

15:45 | Closing Remarks from Workshop Co-Chairs
Marc Glogovsky, MS,
Business Unit Manager/Senior Consultant - Microbiology, ValSource, Inc.
Christopher A. Murdock, PhD, CQA, Senior Director, Global Quality Systems, Bristol Myers Squibb

Agenda is subject to change.

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

 
The Grand Hyatt Washington is the headquarter hotel for the 2023 PDA Microbial Data Deviation Investigations Workshop!

The Workshop hotel room block is closed. We recommend calling the Grand Hyatt for reservations or booking online for the best available rate.

Reservations

Phone: +1 (202) 582-1234
Online:
Click on the reservation link above


The Grand Hyatt Washington is located in downtown Washington, DC, just blocks away from the National Mall. Immerse yourself in the historic sights, shopping, and alluring nightlife of the nation's capital. Whether you're visiting for business or pleasure, you'll enjoy exceptional comfort and service, as well as a direct connection to the city via the Metro Center station.
How to Get Here
By Air The airports closest to the Grand Hyatt Washington hotel are Reagan National Airport (DCA, 3.6m/5.8km), Dulles International Airport (IAD, 25.3m/40.7km), and Baltimore-Washington International Airport (BWI, 31.5m/50.7km).
By Car The Grand Hyatt Washington hotel is located at 1000 H Street NW, Washington, DC 20001. Both self-parking ($12-45+/day) and valet parking ($34-65+/day) are available.